Dynavax Technologies Co. (NASDAQ:DVAX) Shares Bought by Creative Planning

Creative Planning grew its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 77.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 26,817 shares of the biopharmaceutical company’s stock after purchasing an additional 11,682 shares during the quarter. Creative Planning’s holdings in Dynavax Technologies were worth $299,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of DVAX. Kynam Capital Management LP increased its position in shares of Dynavax Technologies by 180.0% during the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after purchasing an additional 2,725,397 shares during the period. Millennium Management LLC acquired a new position in shares of Dynavax Technologies in the 2nd quarter worth $17,615,000. Great Point Partners LLC grew its holdings in shares of Dynavax Technologies by 87.7% in the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after acquiring an additional 1,109,080 shares during the last quarter. Mizuho Markets Americas LLC grew its holdings in shares of Dynavax Technologies by 37.9% in the 2nd quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after acquiring an additional 323,050 shares during the last quarter. Finally, Swedbank AB acquired a new position in shares of Dynavax Technologies in the 1st quarter worth $3,740,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on DVAX shares. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday. The Goldman Sachs Group decreased their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $13.01 on Friday. The stock has a market cap of $1.70 billion, a PE ratio of 100.08 and a beta of 1.34. The business has a fifty day simple moving average of $11.16 and a 200-day simple moving average of $11.24. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.01.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analysts’ expectations of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same quarter last year, the firm posted $0.03 earnings per share. On average, sell-side analysts anticipate that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.